A plan aiming to streamline clinical trial reporting procedures in some circumstances is now out for consultation.
Medsafe is seeking public feedback on a series of proposed updates to the regulatory guidelines for people conducting clinical trials for medicines and medical devices.
Clinical trials are a core part of a high-performing health system and are a key step in the process of bringing new medicines to market or changing the way medicines are used. However, trials do, by their nature, expose patients to potential benefits, as well as risks, and for this reason are tightly controlled. In some instances, the evidence gathered from these trials will make up part of the data considered by Medsafe and other regulatory authorities when assessing a medicine for approval.
A key change will be the provision of guidance for conducting first-in-human trials. These trials, where a medicine is administered to humans for the first time, are an important part of medicines development, but they are also the phase of trials associated with the greatest risk for participants.
Medsafe has also been working with the New Zealand Association of Clinical Research (NZACRes) to produce a simple guide to safety reporting requirements for those conducting clinical trials. This guide is also being consulted on.
Other updates aim to keep our guidance in line with current best practice. For example, involving consumers and patient advocacy groups in the design and conduct of trials, encouraging the implementation of pharmacovigilance systems and clarifying the responsibilities of those involved in clinical trials.
The last major revision to these guidelines was in 2018, and further updates were put on hold during the Covid-19 pandemic to allow more urgent work to be prioritised. This has also meant that some associated legislation has changed, and the guideline needed to reflect this as well.
A proposed change would also reduce reporting requirements for companies who run their own pharmacovigilance system because they are well set up to respond to any safety issues in a timely manner without needing regulatory input.
The proposed changes should provide further clarity to those involved in conducting clinical trials about their obligations as well as simplifying requirements where possible. However, because the changes are extensive Medsafe is consulting with interested parties.
Submissions can be made through the Medsafe looks forward to submissions from people involved in clinical trials in New Zealand and all comments will be considered. Once the analysis of submissions is complete, the guideline document will be revised based on the feedback.
We will publish the and on the Medsafe website.
